<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-05-21T12:13:10.065Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Surg Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Surg Case Rep</journal-id><journal-id journal-id-type="publisher-id">jscr</journal-id><journal-title-group><journal-title>Journal of Surgical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2042-8812</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400693</article-id><article-id pub-id-type="pmc">PMC12093310</article-id><article-id pub-id-type="doi">10.1093/jscr/rjaf317</article-id><article-id pub-id-type="publisher-id">rjaf317</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00910</subject><subject>jscrep/060</subject></subj-group></article-categories><title-group><article-title>A rare presentation of high-grade serous ovarian carcinoma with ulcerating inguinal lymph node metastasis: a case report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Latifah</surname><given-names>Hassan M</given-names></name><aff>
<institution>Department of Obstetrics and Gynecology</institution>, King Faisal Specialist Hospital and Research Center, Jeddah 23433, <country country="SA">Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Almarzugi</surname><given-names>Ruzanah</given-names></name><aff>
<institution>Department of Obstetrics and Gynecology</institution>, King Faisal Specialist Hospital and Research Center, Jeddah 23433, <country country="SA">Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Bitar</surname><given-names>Hussam</given-names></name><aff>
<institution>Department of Surgery, King Faisal Specialist Hospital and Research Center</institution>, <country country="SA">Jeddah 23433, Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Alyafi</surname><given-names>Mohammad</given-names></name><aff>
<institution>Department of Obstetrics and Gynecology, Faculty of Medicine, King Abdulaziz University</institution>, <addr-line>Jeddah 22254</addr-line>, <country country="SA">Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Abumohssin</surname><given-names>Abdulmalik</given-names></name><aff>
<institution>Department of Radiology, King Faisal Specialist Hospital and Research Center</institution>, <country country="SA">Jeddah 23433, Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Almansouri</surname><given-names>Zuhoor</given-names></name><aff>
<institution>Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center</institution>, <country country="SA">Jeddah 23433, Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Kabli</surname><given-names>Batool Abdulaziz</given-names></name><aff>
<institution>College of Medicine, Umm Al-Qura University</institution>, <country country="SA">Makkah 21955, Saudi Arabia</country></aff></contrib><contrib contrib-type="author"><name><surname>Shafi</surname><given-names>Nusaybah A</given-names></name><aff>
<institution>College of Medicine, Umm Al-Qura University</institution>, <country country="SA">Makkah 21955, Saudi Arabia</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0427-8758</contrib-id><name><surname>Baradwan</surname><given-names>Saeed</given-names></name><!--dr.saeed_bardwan@yahoo.com--><aff>
<institution>Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center</institution>, Jeddah 23433, <country country="SA">Saudi Arabia</country></aff><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="cor1">Corresponding author. Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. E-mail: <email>dr.saeed_bardwan@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-05-21"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><volume>2025</volume><issue>5</issue><elocation-id>rjaf317</elocation-id><history><date date-type="received"><day>29</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>Published by Oxford University Press and JSCR Publishing Ltd. &#x000a9; The Author(s) 2025.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="rjaf317.pdf"/><abstract><title>Abstract</title><p>High-grade serous ovarian carcinoma (HGSOC) typically spreads within the peritoneal cavity, and metastatic spread to extraperitoneal lymph nodes, particularly the inguinal region, is rare. Herein, we present a case of a 47-year-old premenopausal woman who presented with an enlarging, ulcerating right inguinal mass. Imaging revealed a necrotic inguinal mass, with no significant intra-abdominal findings. Surgical excision was performed, and histopathology confirmed metastatic HGSOC. She then underwent neoadjuvant chemotherapy, followed by radiotherapy. She then underwent robotic-surgical staging. Histopathological analysis showed bilateral ovarian involvement with multiple tumor foci. Genetic testing identified a BRCA1 mutation, leading to adjuvant maintenance therapy with Olaparib. This case emphasizes the importance of considering ovarian carcinoma in the differential diagnosis of unusual inguinal lymph node masses, even without a visible ovarian mass. Early detection, genetic testing, and a multidisciplinary approach are essential for optimizing patient outcomes in advanced HGSOC with atypical metastasis.</p></abstract><kwd-group><kwd>high grade epithelial ovarian cancer</kwd><kwd>inguinal lymph node</kwd><kwd>lymphatic spread</kwd><kwd>distant metastasis</kwd></kwd-group><counts><page-count count="4"/></counts></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>High-grade serous ovarian carcinoma (HGSOC) is the most frequent and aggressive histologic subtype of epithelial ovarian cancer, repeatedly presenting at an advanced stage due to its insidious onset and lack of early symptoms [<xref rid="ref1" ref-type="bibr">1</xref>]. The disease primarily spreads through transcoelomic dissemination within the peritoneal cavity, with frequent metastatic locations involving the omentum, peritoneum, and distant organs such as the liver and lungs [<xref rid="ref2" ref-type="bibr">2</xref>]. However, extraperitoneal lymphatic spread, particularly to the inguinal lymph nodes, is an uncommon occurrence and is rarely registered in the literature [<xref rid="ref3" ref-type="bibr">3</xref>].</p><p>Lymphatic dissemination of HGSOC typically follows a retroperitoneal pathway, involving the pelvic and para-aortic lymph nodes [<xref rid="ref2" ref-type="bibr">2</xref>]. Inguinal lymph node metastasis, especially presenting as an ulcerated mass, is exceedingly rare [<xref rid="ref3" ref-type="bibr">3</xref>] and poses a diagnostic challenge, often mimicking other malignancies or primary cutaneous lesions. This atypical presentation may lead to delays in diagnosis and modifications in management strategies.</p><p>In this case report, we present an unusual manifestation of HGSOC, characterized by an ulcerating inguinal lymph node metastasis in a patient with advanced disease but no gross ovarian mass on imaging. Through this report, we aim to highlight the diagnostic challenges, possible pathophysiologic mechanisms, and clinical implications of this rare metastatic pattern.</p></sec><sec id="sec2"><title>Case report</title><p>A 47-year-old premenopausal nulliparous woman with an unremarkable medical history presented with a progressively enlarging, painful right inguinal mass. She denied constitutional symptoms such as weight loss, night sweats, or fever. On examination, the mass measured 8&#x02009;&#x000d7;&#x02009;5&#x02009;&#x000d7;&#x02009;7&#x000a0;cm, was fungating, fixed to surrounding structures, and exhibited minimal bleeding.</p><p>Laboratory tests showed an elevated CA-125 level of 531.7&#x000a0;U/mL. Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) of the abdomen and pelvis depicted a large necrotic right inguinal mass measuring 5.3&#x02009;&#x000d7;&#x02009;6.2&#x02009;&#x000d7;&#x02009;8.5&#x000a0;cm, ulcerating into the skin, and closely abutting adjacent inguinal vessels. No significant intra-abdominal lymphadenopathy or thoracic metastases were detected (<xref rid="f1" ref-type="fig">Fig. 1</xref>).</p><fig position="float" id="f1"><label>Figure 1</label><caption><p>Radiological imaging of the right inguinal mass. (a) Contrast-enhanced CT scans of the abdomen and pelvis in axial (left) and sagittal (right) views, demonstrating a pathologically enlarged necrotic right inguinal lymph node (red arrow), measuring 5.3&#x02009;&#x000d7;&#x02009;6.2&#x02009;&#x000d7;&#x02009;8.5&#x000a0;cm. The mass is ulcerating into the inguinal skin and is in very close proximity to the adjacent inguinal vessels. (b) MRI of the pelvis in T1-weighted (left) and T2-weighted (right) sequences, again revealing the pathologically enlarged necrotic right inguinal lymph node (red arrow).</p></caption><graphic xlink:href="rjaf317f1" position="float"/></fig><p>Given the nature of the mass, the patient underwent urgent surgical excision (<xref rid="f2" ref-type="fig">Fig. 2</xref>). However, Due to the tumor abutting the femoral vessels, complete resection was not possible. Histopathological examination established metastatic high-grade serous carcinoma of M&#x000fc;llerian origin, with tumor cells positive for CK7, PAX8, P53 (diffuse and strong), and P16 (diffuse and strong), while negative for CK20, CDX2, TTF1, and GATA3 (<xref rid="f3" ref-type="fig">Fig. 3</xref>). An endometrial biopsy demonstrated weakly proliferative endometrium with reactive changes, and a pap smear was negative for malignancy.</p><fig position="float" id="f2"><label>Figure 2</label><caption><p>Gross image of the partially resected right inguinal mass showing nodularity and ulceration.</p></caption><graphic xlink:href="rjaf317f2" position="float"/></fig><fig position="float" id="f3"><label>Figure 3</label><caption><p>Histopathological and immunohistochemical analysis of the partially resected inguinal mass. (a) Higher magnification of hematoxylin and eosin (&#x000d7;100) revealed pleomorphic neoplastic cells with a high nuclear-to-cytoplasmic ratio, prominent nucleoli, and frequent mitoses. (b) Hematoxylin and eosin (&#x000d7;20) stained slides showed infiltrative carcinoma with glandular, cribriform, and solid growth patterns, overlaid by skin. Immunohistochemical analysis (&#x000d7;100) revealed that the tumor cells stained positive for (c) TP53 and (d) PAX8.</p></caption><graphic xlink:href="rjaf317f3" position="float"/></fig><p>Following confirmation of metastatic ovarian carcinoma, the patient received six cycles of neoadjuvant combinational chemotherapy of paclitaxel and carboplatin, followed by radiotherapy. After 6&#x000a0;months of treatment, her CA-125 level decreased to 7.8&#x000a0;U/mL. She subsequently underwent robotic-assisted total abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic lymph node dissection, and infracolic omentectomy with peritoneal washing. The intraoperative findings clearly indicated markedly enlarged right pelvic nodes, with the largest measuring 3.5&#x02009;&#x000d7;&#x02009;2.3&#x000a0;cm. These nodes were successfully resected during the surgical procedure.</p><p>Histopathological analysis revealed bilateral ovarian involvement with multiple tumor foci, the largest measuring 0.8&#x000a0;cm, but no surface invasion. The right fallopian tube also showed tumor involvement. The lymph nodes examined were negative for malignancy and complete pathological response following treatment with chemotherapy and radiotherapy. However, atypical cells were detected in the pelvic washings.</p><p>Genetic testing confirmed a BRCA1 mutation, prompting the tumor board to recommend adjuvant maintenance therapy with olaparib under the supervision of the medical oncology team. Additionally, the patient was referred to breast surgery for evaluation of a risk-reducing bilateral mastectomy. Ongoing surveillance by the gynecologic oncology team included regular CA-125 monitoring and imaging as needed. At 6&#x000a0;months, there was no clinical or radiological proof of relapse, and the patient was doing well.</p></sec><sec id="sec3"><title>Discussion</title><p>HGSOC is an aggressive malignancy that frequently presents at an advanced stage, often with peritoneal carcinomatosis and widespread intraperitoneal dissemination. While retroperitoneal lymph node involvement, particularly of the pelvic and para-aortic nodes, is a well-recognized feature of HGSOC [<xref rid="ref2" ref-type="bibr">2</xref>], extraperitoneal lymphatic spread is uncommon [<xref rid="ref3" ref-type="bibr">3</xref>]. This case report highlights a rare presentation of HGSOC with an ulcerating inguinal lymph node metastasis, an atypical pattern of dissemination that poses diagnostic and therapeutic challenges.</p><p>The presence of an ulcerating inguinal lymph node mass in a patient without a known primary malignancy often leads to a broad differential diagnosis, including cutaneous malignancies such as squamous cell carcinoma or melanoma, primary lymphomas, and metastatic disease from gynecologic, gastrointestinal, or genitourinary cancers [<xref rid="ref4" ref-type="bibr">4</xref>]. In this case, the absence of an obvious ovarian mass on imaging further complicated the diagnostic process, necessitating histopathological and immunohistochemical confirmation to establish the M&#x000fc;llerian origin of the tumor.</p><p>Inguinal lymph node metastasis from ovarian carcinoma is extremely rare due to the typical routes of HGSOC spread, which include transcoelomic dissemination within the peritoneal cavity and retroperitoneal lymphatic spread [<xref rid="ref2" ref-type="bibr">2</xref>]. Diagnosing metastatic ovarian carcinoma in an inguinal lymph node is particularly difficult when no ovarian mass or peritoneal disease is present. In these cases, immunohistochemical markers are essential for a definitive diagnosis. Positive expression of CK7, PAX8, and p53, along with the absence of CK20, CDX2, and TTF1, provides strong evidence for high-grade serous carcinoma of M&#x000fc;llerian origin [<xref rid="ref5" ref-type="bibr">5</xref>].</p><p>Lymphatic spread in HGSOC typically follows a stepwise pattern, involving the pelvic, para-aortic, and supradiaphragmatic lymph nodes [<xref rid="ref2" ref-type="bibr">2</xref>]; however, alternative lymphatic pathways may occasionally lead to the rare inguinal metastasis [<xref rid="ref3" ref-type="bibr">3</xref>]. Possible mechanisms for this rare dissemination include (i) aberrant lymphatic drainage, where tumor cells bypass the usual retroperitoneal routes due to anomalous connections between the peritoneal and inguinal lymphatic systems; (ii) lymphovascular invasion with retrograde spread, particularly when primary lymphatic pathways are obstructed; and (iii) direct tumor extension along lymphovascular structures or soft tissues, facilitating inguinal involvement. While these mechanisms remain speculative, the presence of an ulcerated inguinal mass in the current case suggests an advanced disease process with extensive lymphovascular dissemination. The tumor&#x02019;s involvement of the inguinal vessels further supports the possibility of direct lymphovascular invasion as a contributing factor.</p><p>The involvement of inguinal lymph nodes in HGSOC is classified as distant metastasis [International Federation of Gynecology and Obstetrics (FIGO) Stage IVB], significantly altering the prognosis and therapeutic considerations [<xref rid="ref6" ref-type="bibr">6</xref>]. Patients with extraperitoneal metastases typically have a poorer prognosis due to the more extensive disease burden and increased likelihood of treatment resistance [<xref rid="ref7" ref-type="bibr">7</xref>]. However, despite the advanced stage, this patient demonstrated an excellent response to chemotherapy, with normalization of CA-125 levels and no residual tumor after surgical intervention. Several investigations [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>] have shown that ovarian cancer patients classified as stage IVB exclusively due to inguinal lymph node metastases have survival rates comparable to those with para-aortic or pelvic lymph node involvement and significantly better outcomes than patients with distant organ metastases. Therefore, the authors of this case report do not support reclassifying these patients as stage IVB.</p><p>The presence of a BRCA1 mutation in this patient is of particular significance, as BRCA-mutated HGSOC is often more responsive to platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) blockers [<xref rid="ref10" ref-type="bibr">10</xref>]. This underscores the vital role of genetic testing in treatment planning and identifying candidates for targeted therapies like olaparib, which has been shown to significantly improve progression-free survival (PFS) in these patients [<xref rid="ref11" ref-type="bibr">11</xref>].</p><p>Managing HGSOC with atypical metastases requires a multimodal approach, incorporating surgery, chemotherapy, and targeted therapy. In this case, the ulcerating and vascularly abutted inguinal mass precluded complete resection at initial presentation, necessitating neoadjuvant chemotherapy to reduce tumor burden before definitive cytoreductive surgery. The patient was managed with a standard regime of paclitaxel plus carboplatin, which remains the first-line therapy for advanced HGSOC [<xref rid="ref12" ref-type="bibr">12</xref>], demonstrating a significant reduction in CA-125 levels and radiologic tumor response. While radiotherapy is not yet recognized as a standard treatment for HGSOC [<xref rid="ref13" ref-type="bibr">13</xref>], it deserves serious consideration for its potential to target residual tumors that are in close proximity to femoral vessels and are deemed inoperable. Given the presence of a BRCA1 mutation, maintenance therapy with the PARP inhibitor olaparib was initiated, as it has been illustrated to increase PFS in BRCA-mutated HGSOC [<xref rid="ref11" ref-type="bibr">11</xref>]. Additionally, the BRCA1 mutation prompted discussions regarding risk-reducing strategies, including prophylactic bilateral mastectomy, highlighting the importance of genetic counseling and long-term surveillance in comprehensive patient management [<xref rid="ref14" ref-type="bibr">14</xref>].</p><p>Given the advanced stage at diagnosis, rigorous long-term follow-up is vital for promptly identifying recurrence and managing the disease. Regular monitoring of CA-125 levels is crucial, as it helps track progression despite its limitations as a definitive marker. Periodic imaging, such as CT scans and MRIs, is essential for detecting recurrence, especially in atypical metastatic patterns. Additionally, thorough clinical assessments during follow-up visits are critical for uncovering early signs of recurrence. This proactive approach ensures timely intervention and significantly enhances patient outcomes.</p></sec><sec id="sec4"><title>Conclusion</title><p>This case highlights the prominence of contemplating ovarian carcinoma in the differential diagnosis of ulcerating inguinal lymph node masses, even in the absence of a detectable ovarian mass. Furthermore, the role of BRCA1 mutation in guiding therapy underlines the necessity for genetic checking in all patients with HGOSC. This case also highlights the evolving landscape of ovarian cancer treatment, where the integration of targeted therapies and individualized treatment strategies is improving survival and quality of life for patients with advanced disease.</p></sec></body><back><sec sec-type="COI-statement" id="sec5"><title>Conflict of interest statement</title><p>None declared.</p></sec><sec id="sec6"><title>Funding</title><p>None declared.</p></sec><ref-list id="bib1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Punzon-Jimenez</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Lago</surname> &#x000a0;<given-names>V</given-names></string-name>, <string-name><surname>Domingo</surname> &#x000a0;<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Molecular Management of high-grade serous ovarian carcinoma</article-title>. <source>Int J Mol Sci</source> &#x000a0;<year>2022</year>;<volume>23</volume>:13777. <pub-id pub-id-type="doi">10.3390/ijms232213777</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bayraktar</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Chen</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Corvigno</surname> &#x000a0;<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Ovarian cancer metastasis: looking beyond the surface</article-title>. <source>Cancer Cell</source> &#x000a0;<year>2024</year>;<volume>42</volume>:<fpage>1631</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2024.08.016</pub-id><pub-id pub-id-type="pmid">39270645</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stavros</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Potiris</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Machairiotis</surname> &#x000a0;<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Inguinal lymph node metastasis as sole manifestation of ovarian/fallopian tube cancer: a review of the literature</article-title>. <source>J Cancer</source> &#x000a0;<year>2023</year>;<volume>14</volume>:<fpage>3176</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.7150/jca.88863</pub-id><pub-id pub-id-type="pmid">37928416</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zaren</surname> &#x000a0;<given-names>HA</given-names></string-name>, <string-name><surname>Copeland</surname> &#x000a0;<given-names>EM</given-names> &#x000a0;<suffix>3rd.</suffix></string-name></person-group> &#x000a0;<article-title>Inguinal node metastases</article-title>. <source>Cancer</source> &#x000a0;<year>1978</year>;<volume>41</volume>:<fpage>919</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(197803)41:3&#x0003c;919::AID-CNCR2820410320&#x0003e;3.0.CO;2-A</pub-id><pub-id pub-id-type="pmid">638977</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Santoro</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Angelico</surname> &#x000a0;<given-names>G</given-names></string-name>, <string-name><surname>Travaglino</surname> &#x000a0;<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features</article-title>. <source>Crit Rev Oncol Hematol</source> &#x000a0;<year>2025</year>;<volume>208</volume>:<fpage>104603</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2024.104603</pub-id><pub-id pub-id-type="pmid">39732305</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Berek</surname> &#x000a0;<given-names>JS</given-names></string-name>, <string-name><surname>Kehoe</surname> &#x000a0;<given-names>ST</given-names></string-name>, <string-name><surname>Kumar</surname> &#x000a0;<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Cancer of the ovary, fallopian tube, and peritoneum</article-title>. <source>Int J Gynaecol Obstet</source> &#x000a0;<year>2018</year>;<volume>143</volume>:<fpage>59</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1002/ijgo.12614</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deng</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Yang</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Tan</surname> &#x000a0;<given-names>Q</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients</article-title>. <source>Gynecol Oncol</source> &#x000a0;<year>2018</year>;<volume>150</volume>:<fpage>460</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2018.06.022</pub-id><pub-id pub-id-type="pmid">30001833</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nasioudis</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>Chapman-Davis</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Frey</surname> &#x000a0;<given-names>MK</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?</article-title> &#x000a0;<source>Gynecol Oncol</source> &#x000a0;<year>2017</year>;<volume>147</volume>:<fpage>81</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2017.07.124</pub-id><pub-id pub-id-type="pmid">28716307</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hjerpe</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Staf</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Dahm-Kahler</surname> &#x000a0;<given-names>P</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study</article-title>. <source>Acta Oncologica (Stockholm, Sweden)</source> &#x000a0;<year>2018</year>;<volume>57</volume>:<fpage>331</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/0284186X.2017.1400691</pub-id><pub-id pub-id-type="pmid">29130381</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Paik</surname> &#x000a0;<given-names>J</given-names></string-name>
</person-group>. <article-title>Olaparib: a review as first-line maintenance therapy in advanced ovarian cancer</article-title>. <source>Target Oncol</source> &#x000a0;<year>2021</year>;<volume>16</volume>:<fpage>847</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/s11523-021-00842-1</pub-id><pub-id pub-id-type="pmid">34623572</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tattersall</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Ryan</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Wiggans</surname> &#x000a0;<given-names>AJ</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer</article-title>. <source>Cochrane Database Syst Rev</source> &#x000a0;<year>2022</year>;<volume>2</volume>:<fpage>CD007929</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD007929.pub4</pub-id><pub-id pub-id-type="pmid">35170751</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ngoi</surname> &#x000a0;<given-names>NY</given-names></string-name>, <string-name><surname>Syn</surname> &#x000a0;<given-names>NL</given-names></string-name>, <string-name><surname>Goh</surname> &#x000a0;<given-names>RM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer</article-title>. <source>Cochrane Database Syst Rev</source> &#x000a0;<year>2022</year>;<volume>2</volume>:<fpage>CD012007</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD012007.pub2</pub-id><pub-id pub-id-type="pmid">35188221</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Macchia</surname> &#x000a0;<given-names>G</given-names></string-name>, <string-name><surname>Titone</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Restaino</surname> &#x000a0;<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Is it time to reassess the role of radiotherapy treatment in ovarian cancer?</article-title> &#x000a0;<source>Healthcare (Basel)</source> &#x000a0;<year>2023</year>;<volume>11</volume>:2413. <pub-id pub-id-type="doi">10.3390/healthcare11172413</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bertozzi</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Londero</surname> &#x000a0;<given-names>AP</given-names></string-name>, <string-name><surname>Xholli</surname> &#x000a0;<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Risk-reducing breast and gynecological surgery for BRCA mutation carriers: a narrative review</article-title>. <source>J Clin Med</source> &#x000a0;<year>2023</year>;<volume>12</volume>:1422. <pub-id pub-id-type="doi">10.3390/jcm12041422</pub-id></mixed-citation></ref></ref-list></back></article>